Dompé Farmaceutici

Dompé Farmaceutici is a privately held pharmaceutical company based in Milan. Founded as a compounding pharmacy in 1890 by Piedmontese Onorato Dompé, the company has grown to a global pharmaceutical company with around 800 employees.[1] His son, Sergio Dompe is the current CEO.[1]

In 2012, Dompé acquired the eye health-focused Italian pharmaceutical company Anabasis Srl;[2] they went on to develop the Anabasis product cenegermin, an eye drop containing recombinant human nerve growth factor, as a treatment for neurotrophic keratitis.[3] Cenegermin was approved by the FDA in August 2018 as the first available treatment for neurotrophic keratitis, and received orphan drug designation. Cenegermin is marketed under the name Oxervate.[4] In the same year, the company announced plans to list shares as part of its move to focus on biotechnology and the treatment of specific diseases.[1]

References
  1. "Italy's Dompe Farmaceutici mulls listing as part of shift to biotech". Reuters. 25 October 2018. Retrieved 20 February 2023.
  2. "Dompé to acquire 100% of Anabasis, an Italian biopharmaceutical ophthalmology company". Business Wire. 28 February 2012. Retrieved 20 February 2023.
  3. "Cenegermin - Dompe Farmaceutici". Adis Insight. 11 February 2022. Retrieved 20 February 2023.
  4. "FDA approves first drug for neurotrophic keratitis, a rare eye disease". FDA. Retrieved 20 February 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.